Physician profile
Daysi Baez
NPI 1326073289
$23,029.53
in general payments reported to CMS, 2019-2025
55 companies · $3,507 in 2025
The $3,507 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,184 · 2020: $2,769 · 2021: $2,774 · 2022: $2,975 · 2023: $3,230 · 2024: $3,590 · 2025: $3,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,281.51 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,581.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,722.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,314.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,243.27 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $1,225.73 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,120.81 | 2019-2025 | Trulance, Xifaxan |
| Amarin Pharma, INC. | $1,005.27 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $840.56 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $822.49 | 2019-2025 | Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $790.70 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $703.53 | 2019-2025 | Zoryve, Livalo |
| Scilex Pharmaceuticals INC. | $509.98 | 2022-2025 | Ztlido |
| Janssen Pharmaceuticals, INC | $478.31 | 2019-2022 | |
| Pfizer INC. | $471.06 | 2019-2025 | |
| Astellas Pharma US INC | $399.69 | 2019-2025 | Veozah |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $341.04 | 2023-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $300.62 | 2024-2025 | Gemtesa, Myfembree |
| E.R. Squibb & Sons, L.L.C. | $299.33 | 2019-2024 | Camzyos, Eliquis |
| Intra-Sana Laboratories | $299.31 | 2023-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Exact Sciences Corporation | $284.51 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $259.30 | 2022-2025 | Contrave, Nexletol, Nexlizet |
| Esperion Therapeutics, INC. | $254.50 | 2020-2025 | Nexletol |
| Ardelyx, INC. | $233.98 | 2025 | Ibsrela |
| Cumberland Pharmaceuticals, INC. | $205.04 | 2021-2024 | Kristalose |
| Sanofi-Aventis U.S. LLC | $199.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $176.34 | 2019-2025 | |
| Allergan, INC. | $156.36 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $153.08 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.19 | 2019-2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $138.74 | 2021-2024 | Dupixent |
| Hikma Pharmaceuticals USA | $134.86 | 2022-2023 | Ryaltris, Mitigare |
| Daiichi Sankyo INC. | $119.12 | 2022-2024 | Injectafer |
| Amneal Pharmaceuticals LLC | $117.77 | 2022-2023 | Unithroid |
| Azurity Pharmaceuticals, INC. | $108.12 | 2024-2025 | Horizant, Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $100.38 | 2021-2025 | |
| Vivus LLC | $83.99 | 2020-2024 | Qsymia |
| Akebia Therapeutics INC | $79.27 | 2019 | |
| Abbott Laboratories | $64.10 | 2021-2022 | |
| Cequr Corporation | $57.90 | 2023-2024 | Cequr Simplicity |
| Eisai INC. | $48.88 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $44.30 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $42.94 | 2022 | |
| Dexcom, INC. | $41.21 | 2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $37.75 | 2023-2024 | Accrufer |
| Horizon Therapeutics Plc | $37.01 | 2019 | |
| Genzyme Corporation | $36.86 | 2021 | |
| Xeris Pharmaceuticals, INC. | $35.91 | 2023 | Gvoke Hypopen |
| Vistapharm, INC. | $32.24 | 2021 | |
| Bausch Health US, LLC | $26.15 | 2019 | |
| Genentech USA, INC. | $20.83 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.32 | 2021 | |
| Renalytix Ai, INC. | $17.14 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Madrigal Pharmaceuticals | $17.14 | 2024 | Resmetirom |
| Ibsa Pharma INC. | $16.73 | 2020 | |
| Gilead Sciences, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daysi Baez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.